.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,772,475

« Back to Dashboard

Claims for Patent: 4,772,475

Title: Controlled-release multiple units pharmaceutical formulation
Abstract:A pharmaceutical controlled-release individual unit or multiple units formulation in which the individual unit comprises a granulation product obtained by adding a release controlling agent to a mixture of a physiologically active substance and units-forming substance(s) and granulating and resultant mixture, said granulation product (granules) being substantially not disintegrated but gradually releasing the physiologically active substance in the gastrointestinal tract.
Inventor(s): Fukui; Muneo (Saitama, JP), Tomuro; Kouji (Saitama, JP), Masuyama; Shigeru (Saitama, JP), Kajiyama; Atsushi (Saitama, JP), Hikosaka; Tamio (Saitama, JP), Aruga; Masayoshi (Saitama, JP), Higuchi; Saburo (Saitama, JP), Soeishi; Yoshiaki (Tokyo, JP)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:06/833,961
Patent Claims: 1. A pharmaceutical controlled-release individual unit or multiple unit formulation in which said individual unit consists essentially a granulation product obtained by adding a release controlling agent selected from the group consisting of acrylic acid polymers, acrylic acid copolymers and mixtures thereof with cellulose derivatives, to a mixture of physiologically active substances and crystalline cellulose, in an amount such that at least 50% by weight based on the weight of the units is said crystalline cellulose and granulating the resultant mixture and wherein said granulation product does not substantially disintegrate but gradually releases the physiologically active substance in the gastrointestinal tract.

2. The pharmaceutical formulation as claimed in claim 1, wherein the release controlling agent is a methacrylic acid-ethyl acrylate copolymer or mixtures of said copolymer and ethyl cellulose.

3. The pharmaceutical formulation as claimed in claim 1, wherein the release controlling agent further contains water.

4. The pharmaceutical formulation as claimed in claim 1, 2, or 3, wherein the physiologically active substance is 5-{2-[2-(o-ethoxypheoxy)ethylamino]propyl}-2-methoxybenzenesulfonamide hydrochloride (YM-12617).

5. The pharmaceutical formulation as claimed in claim 1, 2, 3, or 4, wherein the individual unit is granulation product having diameter of 0.1 to 1.5 mm.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc